Articles
Rare disease pricing – is it sustainable?

Rare disease pricing – is it sustainable?

Doug Paul takes the reins on Siren’s fourth of five rare disease articles and looks into the challenges of orphan drug pricing and reimbursement. Before assessing the future, let us first make sure we understand an important element of the past. In the United States in the...

Articles
Rare disease research: the current and future state

Rare disease research: the current and future state

Today is Rare Disease Day – this article, which is the last in the series by Siren Interactive, is an interview between Wendy White and PPMD CEO, Pat Furlong, about the importance of rare disease research. It is estimated that 95 percent of rare diseases do not have an FDA approved therapy. As a result, research is...

Articles
Rare disease perspectives from patients and caregivers

Rare disease perspectives from patients and caregivers

Have you ever wondered what it must be like to live with a rare disease as a patient or caregiver? Watch our video to hear some first-hand accounts. We spoke with several rare disease patients and caregivers and asked them to share their personal experiences with us...

Sales & Marketing

Digital

Market Access

Editor's Picks

  1. NICE finally backs Enhertu for HER2-low breast cancer
  2. Novo Nordisk rebrands as Novo as new CEO charts turnaround
  3. MPs seek probe into UK-US pharma deal's impact on NHS
  4. FDA unveils framework for its expedited IND pilot
  5. WCLC: Lung cancer news from BioNTech, Akeso, and Roche

Newsletters and Deep Dive
digital magazine

Oncology

Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

more

Patients

more

R&D

more